Calcinate

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcinate

Property Description
Active ingredient Calcium Gluconate
Form Solution for Injection, Oral Tablets
Pharmacological class Mineral Supplement, Electrolyte Replacer
Common use Essential Mineral Replacement, Electrolyte Homeostasis
Origin Synthetic

The Definitive Classification of Calcinate

Calcinate is a prescription-status preparation whose active component is Calcium Gluconate, classifying it fundamentally as a Mineral Supplement and an Electrolyte Replacer, utilized to restore and maintain the body’s essential mineral status. This specific Calcium Salt Preparation is noted for its high tolerability, distinguishing it from related salts like calcium chloride. Calcium salts are utilized in managing conditions resulting from low calcium levels in the bloodstream. This means the medicine provides a source of calcium when the body's natural reserves are insufficient. The compound is synthesized in a lab, defining it as a Synthetic substance, and is structurally a Single-ingredient product, which allows for focused intervention in cases of mineral deficiency.

Forms, Composition, and General Role

The preparation is available in distinct Dosage Forms, primarily a sterile Solution for Injection and Oral Tablets, reflecting its use in both acute situations and long-term nutritional support. The injectable form consists of Calcium Gluconate dissolved in an Aqueous solution for Parenteral Use, while the tablets incorporate Solid excipients for Oral Administration. Calcium compounds are categorized as Essential Medicines, reflecting their role in public health and primary care. The general purpose of this medicine is the delivery of Ionic Calcium for Essential Mineral Replacement, which is required for supporting multiple physiological processes, including the function of nerve and muscle cells. This action aids in maintaining Electrolyte Homeostasis, thereby addressing the systemic disruptions associated with Calcium Deficiency (Hypocalcemia).

Regulatory References

  1. National Library of Medicine (NLM)
  2. PubMed
  3. World Health Organization
  4. Calcium Gluconate on the WHO Essential Medicines List

What side effects are possible with Calcinate?

Possible Side Effects and Safety Information

The safety profile of Calcinate (Calcium Gluconate Injection) is structured around risks associated with the method of administration and the maintenance of essential mineral balance, as documented by government regulatory agencies.

Documented Adverse Reactions

Adverse events often relate to the rate of administration or extravasation (leakage outside the vein). Frequencies for many injection-related effects are generally classified as Not Known.

System-Organ Class Examples of Documented Reactions
Cardiovascular Bradycardia, Cardiac Arrhythmia, Hypotension, Vasodilation
Administration Site Local Necrosis, Calcinosis Cutis, Local Soft Tissue Inflammation
Gastrointestinal Nausea, Vomiting (often signs of over-replacement)
Systemic Heat Sensations, Flushing

Serious Safety Considerations

Regulatory documents list several serious adverse reactions, which are typically associated with rapid intravenous delivery or complications of injection:

  • Cardiac Arrest or Circulatory Collapse (following rapid administration).
  • Tissue Necrosis (tissue death) from extravasation.
  • End-Organ Damage due to the formation of precipitates, specifically if administered with intravenous Ceftriaxone.

Population-Specific Safety Statements

Specific restrictions and warnings exist for certain patient groups:

  • Neonates (le 28 days): The medicine is contraindicated if the patient is receiving intravenous Ceftriaxone due to the risk of fatal precipitation.
  • Renal Impairment: Requires cautious use and close monitoring of serum calcium levels.
  • Cardiac Glycoside Use: Use must be avoided or managed with extreme caution and continuous monitoring due to the risk of synergistic arrhythmias.

Official Safety Restrictions

Contraindications include pre-existing Hypercalcemia (high calcium levels). The label also notes that adverse cardiovascular reactions are explicitly linked to rapid intravenous administration, establishing delivery speed as a critical safety factor.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Calcinate (Calcium Gluconate) primarily leads to hypercalcemia, a documented condition of excessively high serum calcium levels. The official regulatory profile describes specific clinical manifestations and mandates immediate emergency action when an overdose is suspected.

Documented Overdose Manifestations

Symptoms of hypercalcemia include systemic effects such as nausea, vomiting, abdominal pain, muscle weakness, and confusion. Patients may also experience increased thirst (polydipsia) and increased urination (polyuria). Severe overdose is associated with life-threatening cardiovascular effects, including cardiac arrhythmias, bradycardia, hypotension, and cardiac arrest, particularly if administration is too rapid.

Required Emergency Actions

Regulators mandate that individuals seek emergency medical attention or contact a Poison Control Center immediately in the event of a suspected overdose. The presence of signs such as a slow or irregular heartbeat or rapid onset of gastrointestinal symptoms requires urgent medical evaluation.

Supportive Measures and Risks

Management of documented overdose involves symptomatic and supportive treatment, with mandatory Close ECG monitoring to detect cardiac complications. If leakage outside the vein (extravasation) occurs, administration must be immediately discontinued due to the risk of severe local injury, including tissue necrosis. Patients with impaired renal function and pediatric patients are noted to be at an increased risk of trace Aluminum Toxicity with prolonged use.

Therapeutic Uses of Calcinate

What Calcinate Treats: Main Uses and Benefits

Calcinate (Calcium Gluconate) is generally used as a mineral supplement and electrolyte replacer applied in therapeutic areas that involve symptomatic relief from systemic imbalance, addressing severe symptomatic patterns and providing supportive benefits across key domains. Calcium Gluconate is indicated for the treatment of acute symptomatic hypocalcemia and is utilized in managing certain toxicities.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including acute symptomatic hypocalcaemia, Hypoparathyroidism, and to manage specific toxic exposures like severe hyperkalaemia, magnesium sulfate overdose, and certain types of poisoning.

Calcinate is applied in clinical settings that involve acute or unstable symptom patterns, relevant in contexts involving heightened systemic burden. This supportive use is primarily relevant for easing symptoms that interfere with daily functioning, such as muscle cramps and tetany, and supports patients during episodes of heightened discomfort related to temporary physiological imbalance.

“It is applied across domains where additional symptomatic support is needed to address symptoms related to heightened physiological activity.”

Quick Fact: Relief for Acute Spasms
Calcinate is commonly used to address neuromuscular hyperexcitability, the symptom cluster behind painful muscle cramps and tetany.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Calcinate?

Eligibility for Calcinate (Calcium Gluconate) use is strictly determined by official regulatory documents, defining both permitted and prohibited populations.

Absolute Contraindications

Calcinate must not be used in patients with hypercalcemia (abnormally high blood calcium levels). Use is also contraindicated in patients receiving intravenous cardiac glycosides (e.g., Digoxin) due to the risk of severe cardiotoxicity. The intravenous injection is also prohibited in neonates (28 days of age or younger) who are concurrently receiving the antibiotic ceftriaxone.

Age and Condition Restrictions

Population Group Regulatory Status Constraint Summary
Adults and Pediatrics Allowed Indicated for acute symptomatic hypocalcemia.
Renal Impairment Restricted / Caution Use requires cautious dosing and close monitoring; repeated or prolonged use is contraindicated if associated with aluminum exposure.
Older (Geriatric) Patients Caution Dosing must be cautious, starting at the low end of the dosage range.
Pregnancy/Lactation Conditional Use Data is insufficient to inform risk; use during pregnancy is reserved for when the woman's clinical condition requires it, and calcium is excreted in breast milk.

Official Eligibility Statements

The medicine is officially allowed for use in adult and pediatric patients [1.5]. Use in populations with heart disease or conditions like sarcoidosis requires special caution and monitoring [4.1, 2.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents establish specific restrictions for the co-administration of Calcinate (Calcium Gluconate) with certain medicinal products, solutions, and supplements. The official interaction profile is defined by physical incompatibilities, pharmacodynamic risks, and changes in systemic calcium exposure.

Contraindicated Combinations

Co-administration of intravenous Calcinate with intravenous Ceftriaxone is formally contraindicated in neonates (28 days of age or younger) due to the risk of precipitate formation in the lungs and kidneys. Additionally, the simultaneous intravenous administration of Calcinate and Ceftriaxone via a Y-site is prohibited in all age groups. Intravenous Calcinate is also generally contraindicated in patients receiving cardiac glycosides (e.g., Digoxin) due to a synergistic effect that increases the risk of serious arrhythmia.

Pharmacodynamic and Exposure Interactions

The product interacts with several drug classes:

  • Cardiac Agents: Calcinate may reduce the therapeutic effect of calcium channel blockers. Use with Digoxin can increase the risk of toxicity and cardiac arrhythmias.
  • Exposure-Altering Agents: Co-administration with agents that increase systemic calcium, such as Thiazide Diuretics and Vitamin D or its analogs, may lead to excessive plasma calcium concentrations.
  • Antibiotics: Calcium complexes certain tetracycline antibiotics, rendering them inactive. Calcinate injection is also physically incompatible with Minocycline Injection.

Administration and Timing Rules

Calcinate Injection is not physically compatible with and must not be mixed with solutions containing bicarbonate or phosphate, as precipitation may result. If sequential administration of IV Ceftriaxone and Calcinate is necessary in patients older than 28 days, the infusion line must be thoroughly flushed between the infusions.

Mechanism of Action

How Calcinate Works: Mechanism of Action

Calcinate is a phosphate binder that acts locally and peripherally within the gastrointestinal (GI) tract to modulate mineral input. Its core mechanism involves a chelation reaction with dietary phosphate. The drug, functioning as a binder, targets negatively charged phosphate ions ingested through food, forming a tight chemical bond.

Intestinal Phosphate Sequestration

This interaction generates a large, insoluble Calcinate-phosphate complex. This complex is physically incapable of passing across the intestinal lining and into the systemic circulation. By sequestering the phosphate within the GI lumen, Calcinate directly limits the amount of the mineral that can be absorbed by the body.

Modulation of Systemic Phosphate Concentration

The consequence of this mechanistic cascade is a reduction in the continuous influx of phosphate from the digestive system into the bloodstream. This modification to the body’s phosphate absorption pathway results in an adjustment of the circulating serum phosphate concentration via altered excretion.

Dosage and Administration Information

How Calcinate is Used: Official Administration Guidelines

Calcinate (Calcium Gluconate) is administered via two primary, officially approved routes: Intravenous (IV) injection for acute, systemic correction and Oral (PO) forms (tablets) for non-acute replacement and maintenance. The use pattern follows standardized clinical practice.


Administration and Dosage

Instruction Category Official Rule/Instruction
Route Hierarchy The solution is for IV use only. Intramuscular (IM) and subcutaneous (SC) routes are prohibited. Oral forms may be taken with or without food.
Adult IV Dosing Initial bolus is 1,000 mg to 2,000 mg. Subsequent doses may be repeated every 6 hours as needed, or a continuous infusion may be initiated.
Infusion Rate Limit The IV infusion rate must not exceed 200 mg/minute in adults and 100 mg/minute in pediatric patients.
Preparation The 100 mg/mL injection must be diluted in compatible IV fluids, such as 5% dextrose or 0.9% sodium chloride, to a specific concentration before administration.

Use Patterns and Restrictions

Intravenous administration is intended for short-term use to stabilize acute conditions; the safety of long-term IV use has not been established. For dosing in patients with renal impairment, administration must be initiated at the lowest recommended dose for the applicable age group. Furthermore, the solution must not be mixed with IV fluids or other medications that contain phosphate or bicarbonate due to the risk of physical incompatibility.

Recent Clinical Evidence

Evidence for Use in Acute Symptomatic Hypocalcemia

Calcinate was studied for its use in individuals experiencing severe, sudden drops in calcium levels, known as symptomatic hypocalcemia. This is an established medicine used in this acute context, and its evidence base is primarily built upon extensive published scientific literature and long-standing expert consensus. Regulators rely on decades of supportive clinical evaluation studies rather than new, large-scale controlled trials. Research focused on measuring changes in serum calcium concentration and monitored outcomes describing episodic or acute changes such as severe muscle spasms. The primary limitation is the absence of large, modern, placebo-controlled trials. The evidence helps show what has been observed so far but does not determine whether an individual will respond similarly.


Evidence for Use in Acute Cardiotoxicity

Research examined the medicine's application in acute settings for changes in cardiac electrical activity in patients presenting with cardiotoxicity linked to severe electrolyte imbalances (hyperkalemia or magnesium sulfate overdose). Studies explored this urgent scenario using physiological data and expert consensus. Research focused on changes recorded via EKG findings. Follow-up durations were naturally limited to the immediate acute period, typically 20 to 60 minutes. Research in this area provides insight into the short-term changes but does not determine long-term outcomes.


Research in Specialized Populations and Specific Conditions

Research has examined Calcinate's use in certain conditions involving periods of heightened symptoms in children (e.g., hypocalcemic seizures) through small-scale Randomized Controlled Trials (RCTs). These studies monitored serum calcium levels and observed patterns related to seizure recurrence. Sample sizes were modest, and comparative evidence is lacking for some strategies. Research is ongoing for new applications, such as evaluating use in women undergoing Cesarean delivery, where pilot studies are still emerging and follow-up durations were limited to 24 hours after delivery.


Gaps in Evidence and Areas Under Ongoing Research

For many contexts, there is limited information for long-term outcomes, as the research primarily examines the acute resolution of the symptom or crisis. Major limitations include regulatory reliance on established literature versus large-scale modern RCTs, and for specialized uses, sample sizes were modest, which makes subgroup findings uncertain. Data for certain groups remain insufficient, particularly for long-term outcomes or when comparing the equivalence of different salt forms.

Key Studies & References

  1. Calcium Gluconate Clinical Summary and Indications (StatPearls)
  2. The Use of Calcium Salts in Hypocalcemia Management (NIH Literature Review)

Frequently Asked Questions (FAQ)

Common questions about Calcinate (FAQ)

Q: Is Calcinate the same as other medicines for the same condition?

Calcinate (Calcium Gluconate) is classified by regulatory agencies as a Mineral and Electrolyte Replacer or Calcium Salt. Official documents establish its role in rapidly restoring low calcium levels in the blood. Official product information focuses on its authorized use and does not provide direct comparisons to other specific medicines.

Q: Why is Calcinate sometimes called [Alternative Name]?

The active ingredient in Calcinate is Calcium Gluconate, which is its generic name and is commonly used in official sources. Calcium Gluconate is the specific chemical form, or calcium salt, used in this medicine.

Q: How quickly does Calcinate start working?

Official information indicates that the intravenous solution of Calcinate is used to rapidly increase calcium concentration in the blood. This rapid action aligns with its use for acute, sudden drops in calcium levels.

Q: How long does it take for Calcinate to show its full effect?

For acute situations requiring intravenous administration, regulatory guidelines require the monitoring of serum calcium levels every few hours. This frequent monitoring suggests that the medicine’s effects are measured and managed over a short timeframe in acute settings.

Q: Can Calcinate make you feel tired or dizzy?

While tiredness and dizziness are not explicitly listed as documented adverse reactions in official labeling, rapid intravenous administration has been associated with hypotension (low blood pressure). The documented adverse reaction of hypotension may be associated with feelings like lightheadedness or fatigue.

Q: What foods or drinks should be avoided when taking Calcinate?

Official guidelines allow oral forms to be administered with or without food. However, consumption of foods high in oxalic acid (found in spinach and rhubarb) or phytic acid (found in bran and whole grains) may affect how the calcium is absorbed.

Q: Is it safe to take Calcinate with vitamins or supplements?

Regulatory documents include warnings about co-administration with supplements that specifically increase systemic calcium, such as Vitamin D or its analogs. Combining these may lead to excessively high calcium concentrations in the blood. The official label notes that concurrent use of any supplement should be managed by a healthcare provider.

Q: Is Calcinate suitable for teenagers?

Official labeling confirms that the safety and effectiveness of the injectable form have been established in pediatric patients, which includes teenagers, for the treatment of acute symptomatic hypocalcemia. Eligibility for use is assessed based on the patient's specific clinical needs.

Q: Does Calcinate require a special diet?

The oral form functions as a phosphate binder, which works to modulate the amount of phosphate absorbed from food in the digestive system. While no specific restrictive diet is mandated, consumption of foods high in certain acids may affect how the calcium is absorbed.

Q: What if I accidentally take two doses of Calcinate?

Regulatory labeling includes a section on overdosage. Signs of overdosage are generally related to hypercalcemia (abnormally high calcium levels), which may include nausea, vomiting, or changes in heart rhythm.

Q: How long do most people stay on Calcinate treatment?

The injectable form is indicated for acute, short-term treatment to stabilize a crisis. Regulatory documents state that the safety of long-term intravenous use has not been established. The duration of therapy is determined by the specific clinical needs of the patient.

Q: Are there any long-term health concerns related to Calcinate?

The official labels state that for the injectable form, the safety of long-term use has not been established, as research primarily examines acute resolution. Data on long-term outcomes remains limited.

Q: Has Calcinate been approved in other countries besides the US?

Official documents from health authorities outside the United States, such as the Australian TGA pregnancy classification, indicate that the product is subject to review, classification, and authorized use in numerous countries globally.

Q: Can Calcinate affect blood pressure readings?

Documented adverse reactions linked to rapid intravenous administration include hypotension (low blood pressure) and vasodilation (widening of blood vessels). These effects mean that the medicine can affect blood pressure readings during administration.

Q: Is Calcinate known to cause any skin reactions or rashes?

The adverse reactions section explicitly documents localized skin reactions associated with the injection site. These include calcinosis cutis (calcium deposits in the skin) and local necrosis (tissue death) from the fluid leaking outside the vein (extravasation).

Q: Is Calcinate available in different strengths?

The injectable solution is officially supplied in concentrations such as 1,000 mg per 50 mL or 2,000 mg per 100 mL (both resulting in a 20 mg/mL concentration) in pre-filled bags. The product is also available in oral tablet form.

Q: Can Calcinate be split or crushed?

Official administration instructions for oral tablets state they may be taken with or without food. However, the official regulatory instructions do not authorize or prohibit splitting or crushing the tablets.

Q: Can men and women take the same dose of Calcinate?

Dosing recommendations provided in regulatory documents are based on the patient’s age (adult or pediatric) and the severity of their hypocalcemia. Official dosing guidelines do not differentiate between recommended doses based on sex.

Q: Is Calcinate part of a drug class that includes other common medications?

Official regulatory classification lists Calcinate (Calcium Gluconate) as belonging to the drug classes of Minerals and Electrolytes and Calcium Salts. These classes include other common preparations used to restore essential mineral balance in the body.

Q: Is Calcinate known to affect liver function?

Regulatory documents state that hepatic impairment (liver dysfunction) is a consideration for its use. However, the label notes that the product does not require the liver to metabolize it to release calcium ions, meaning it remains effective even in the presence of liver function issues.

Q: What are the most common side effects people report with Calcinate?

The official product information documents several adverse reactions related to the administration method, such as cardiovascular changes and site inflammation. However, the official frequency (how common they are) for many of these injection-related effects is generally classified as Not Known.

Q: Is Calcinate safe to use while breastfeeding?

Official documents state that calcium is excreted in breast milk. The regulatory status does not provide a definitive statement on the risk to the infant, reserving use for when the woman's clinical condition requires it.

Q: Does Calcinate interact with common over-the-counter pain relievers?

Regulatory documents detail interactions with specific drug classes like certain antibiotics and cardiac agents. The label does not specifically name or exclude common over-the-counter pain relievers.

Q: What is the difference between generic and brand-name Calcinate?

Calcinate's active ingredient is Calcium Gluconate, which is the generic name. The regulatory information provides the specific chemical details and forms of the active ingredient, but it does not include a direct comparison or evaluation of brand-name versus generic versions.

Q: Do studies support the long-term use of Calcinate?

Official administration documents state that the safety of long-term intravenous use has not been established, and a common limitation in research is the lack of information regarding long-term outcomes. The duration of therapy is determined by the patient’s specific clinical needs.

How should Calcinate be stored and disposed of?

Storage and Disposal of Calcinate (Calcium Gluconate)

The official storage conditions for Calcium Gluconate require the product to be maintained at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F). It is essential that the medicine be protected from freezing at all times. Oral tablets must be kept in a tightly closed container to prevent exposure to moisture, and the injectable solution should be stored in its original vial.

The single-dose injectable form must be discarded immediately after the required dose is withdrawn, and any remaining portion is not to be saved. All forms of the medicine must be stored out of the sight and reach of children.

Disposal of unused or expired Calcium Gluconate must be conducted in accordance with local requirements, typically through an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcinate found in:

A-Z Index: